EVAX
Income statement / Annual
Last year (2024), Evaxion Biotech A/S's total revenue was $3.34 M,
an increase of 4,480.82% from the previous year.
In 2024, Evaxion Biotech A/S's net income was -$10.57 M.
See Evaxion Biotech A/S,s key income statements, including revenue, expenses, profit, and income.
Period |
FY-2024
|
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
Period Ended |
12/31/2024 |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
Operating Revenue |
$3.34 M |
$73.00 K |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
Cost of Revenue |
$0.00
|
$112.00
|
$571.32 K
|
$343.45 K
|
$105.72 K
|
$80.98 K
|
$73.93 K
|
Gross Profit |
$3.34 M
|
$72.89 K
|
-$571.32 K
|
-$343.45 K
|
-$105.72 K
|
-$80.98 K
|
-$73.93 K
|
Gross Profit Ratio |
1
|
1
|
0
|
0
|
0
|
0
|
0
|
Research and Development Expenses |
$10.46 M
|
$11.92 M
|
$17.06 M
|
$19.58 M
|
$10.90 M
|
$8.22 M
|
$3.73 M
|
General & Administrative Expenses |
$7.32 M
|
$10.35 M
|
$8.21 M
|
$6.25 M
|
$5.67 M
|
$2.63 M
|
$1.88 M
|
Selling & Marketing Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
Selling, General & Administrative Expenses |
$7.32 M
|
$10.35 M
|
$8.21 M
|
$6.25 M
|
$5.67 M
|
$2.63 M
|
$1.88 M
|
Other Expenses |
$302.00 K
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$16.00 K
|
$15.00 K
|
Operating Expenses |
$18.08 M
|
$22.25 M
|
$25.26 M
|
$25.83 M
|
$16.57 M
|
$10.86 M
|
$5.63 M
|
Cost And Expenses |
$18.08 M
|
$22.27 M
|
$25.26 M
|
$25.83 M
|
$16.57 M
|
$10.86 M
|
$5.63 M
|
Interest Income |
$254.00 K
|
$154.00 K
|
$2.83 M
|
$2.04 M
|
$216.00 K
|
$9.00 K
|
$2.00 K
|
Interest Expense |
$962.00 K
|
$897.00 K
|
$1.51 M
|
$915.00 K
|
$223.00 K
|
$1.22 M
|
$698.00 K
|
Depreciation & Amortization |
$607.02 K
|
$615.95 K
|
$571.32 K
|
$343.45 K
|
$105.72 K
|
$80.98 K
|
$73.93 K
|
EBITDA |
-$9.77 M |
-$21.40 M |
-$22.58 M |
-$24.17 M |
-$16.46 M |
-$11.90 M |
-$6.18 M |
EBITDA Ratio |
-2.92
|
-293.19
|
0
|
0
|
0
|
0
|
0
|
Operating Income Ratio |
-4.41
|
-304.07
|
0
|
0
|
0
|
0
|
0
|
Total Other Income/Expenses Net |
$3.38 M
|
-$718.00 K
|
$1.32 M
|
$1.12 M
|
-$7.00 K
|
-$1.16 M
|
-$636.93 K
|
Income Before Tax |
-$11.36 M
|
-$22.92 M
|
-$23.94 M
|
-$24.71 M
|
-$16.58 M
|
-$12.02 M
|
-$6.27 M
|
Income Before Tax Ratio |
-3.4
|
-313.9
|
0
|
0
|
0
|
0
|
0
|
Income Tax Expense |
-$788.00 K
|
-$791.22 K
|
-$772.00 K
|
-$178.00 K
|
-$1.56 M
|
-$825.00 K
|
-$735.00 K
|
Net Income |
-$10.57 M
|
-$22.13 M
|
-$23.17 M
|
-$24.53 M
|
-$15.02 M
|
-$11.20 M
|
-$5.54 M
|
Net Income Ratio |
-3.16
|
-303.08
|
0
|
0
|
0
|
0
|
0
|
EPS |
-10 |
-32.44 |
-39.2 |
-50.32 |
-37.08 |
-27.64 |
-11.52 |
EPS Diluted |
-10 |
-32.44 |
-39.2 |
-50.32 |
-37.08 |
-27.64 |
-11.52 |
Weighted Average Shares Out |
$1.07 M
|
$683.40 K
|
$590.97 K
|
$487.33 K
|
$404.97 K
|
$404.97 K
|
$479.97 K
|
Weighted Average Shares Out Diluted |
$1.07 M
|
$683.40 K
|
$590.97 K
|
$487.33 K
|
$404.97 K
|
$404.97 K
|
$479.97 K
|
Link |
|
|
|
|
|
|
|